-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
-
Summary
-
Ambrx Biopharma Cayman, Inc. quarterly Deferred Income Tax Liabilities, Net history and change rate from Q4 2020 to Q2 2023.
- Ambrx Biopharma Cayman, Inc. Deferred Income Tax Liabilities, Net for the quarter ending 30 Jun 2023 was $880,000.000, unchanged year-over-year.
Deferred Income Tax Liabilities, Net, Quarterly (USD)
Deferred Income Tax Liabilities, Net, YoY Quarterly Change (%)